SciVision Biotech Inc. (TPE:1786)

SciVision Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	889.91	706.02	511.1	587.02	658.92	397.36
Short-Term Investments	69.9	99.9	233.9	30.71	36.92	15.94
Cash & Short-Term Investments	959.81	805.92	745	617.73	695.84	413.31
Cash Growth	33.55%	8.18%	20.60%	-11.23%	68.36%	-3.51%
Accounts Receivable	131.13	172.94	95.18	90.34	78.37	67.9
Other Receivables	23.63	1.09	1.02	1.16	0.2	0.33
Receivables	154.75	174.02	96.21	91.49	78.56	68.23
Inventory	82.03	72.23	87.25	95.87	82.9	45.9
Prepaid Expenses	42.01	47.94	15.48	18.65	21.7	24.42
Other Current Assets	125.47	66.3	59.97	57.29	46.24	1.58
Total Current Assets	1,364	1,166	1,004	881.03	925.24	553.45
Property, Plant & Equipment	1,236	1,176	1,135	1,184	1,246	1,296
Other Intangible Assets	1.5	1.68	2.15	2.67	3.38	4.43
Long-Term Deferred Tax Assets	0.26	5.02	15.5	25.04	31.33	31.85
Other Long-Term Assets	8.08	5.01	3.22	5.23	56.48	5.22
Total Assets	2,610	2,354	2,160	2,098	2,262	1,891
Accounts Payable	22.49	13.27	6.75	14.02	5.46	17.11
Accrued Expenses	81.22	135.76	102.56	78.4	-	-
Short-Term Debt	1.01	-	-	-	-	-
Current Portion of Long-Term Debt	-	134.79	-	-	303.37	-
Current Portion of Leases	8.86	4.73	1.22	1.2	1.24	0.79
Current Income Taxes Payable	-	12.65	5.77	13.97	-	8.78
Current Unearned Revenue	1.27	2.68	7.02	0.7	1.71	7.3
Other Current Liabilities	65.11	33.19	21.69	19.79	113.86	87.63
Total Current Liabilities	179.95	337.07	144.99	128.08	425.64	121.61
Long-Term Debt	371.13	-	323.84	386.69	300	296.56
Long-Term Leases	104.84	84.72	22.85	24.1	28.48	23.74
Pension & Post-Retirement Benefits	3.44	8.14	18.92	25.47	35.16	42.64
Long-Term Deferred Tax Liabilities	0.49	4.35	0.03	0.05	-	-
Other Long-Term Liabilities	29.42	23.15	23.03	22.91	22.78	2
Total Liabilities	689.27	457.43	533.67	587.31	812.06	486.55
Common Stock	721.92	717.92	677.1	661.9	661.9	610.05
Additional Paid-In Capital	960.31	844.08	700.34	648.26	638.12	638.12
Retained Earnings	212.92	335.25	249.73	201.61	150.72	156.86
Comprehensive Income & Other	25.45	-0.2	-0.66	-0.84	-0.86	-0.85
Shareholders' Equity	1,921	1,897	1,627	1,511	1,450	1,404
Total Liabilities & Equity	2,610	2,354	2,160	2,098	2,262	1,891
Total Debt	485.84	224.24	347.91	411.99	633.09	321.08
Net Cash (Debt)	473.97	581.69	397.09	205.74	62.75	92.23
Net Cash Growth	-15.14%	46.49%	93.01%	227.89%	-31.96%	-21.16%
Net Cash Per Share	6.43	7.81	5.19	2.76	0.88	1.31
Filing Date Shares Outstanding	72.19	71.79	67.71	66.19	66.19	66.19
Total Common Shares Outstanding	72.19	71.79	67.71	66.19	66.19	66.19
Working Capital	1,184	829.35	858.92	752.95	499.6	431.84
Book Value Per Share	26.60	26.42	24.02	22.83	21.90	21.21
Tangible Book Value	1,919	1,895	1,624	1,508	1,446	1,400
Tangible Book Value Per Share	26.58	26.40	23.99	22.79	21.85	21.15
Land	4.73	4.73	4.73	4.73	9.5	9.5
Buildings	696.75	687.72	686.59	686.32	688.54	184.24
Machinery	998.15	926.47	909.63	896.45	891.02	223.58
Construction In Progress	29.83	20.57	3.5	4.62	0.77	1,186

Source: S&P Global Market Intelligence. Standard template. Financial Sources.